Molecular Templates Inc (NASDAQ:MTEM) rose 12.3% during mid-day trading on Tuesday . The company traded as high as $8.36 and last traded at $8.11, approximately 305,900 shares were traded during mid-day trading. An increase of 188% from the average daily volume of 106,170 shares. The stock had previously closed at $7.22.
MTEM has been the topic of a number of research analyst reports. Zacks Investment Research lowered Molecular Templates from a “hold” rating to a “sell” rating in a research report on Tuesday. Cowen reissued a “buy” rating on shares of Molecular Templates in a research report on Wednesday, November 13th. TheStreet lowered Molecular Templates from a “c-” rating to a “d” rating in a research report on Monday, August 5th. BidaskClub lowered Molecular Templates from a “buy” rating to a “hold” rating in a research report on Friday. Finally, ValuEngine lowered Molecular Templates from a “sell” rating to a “strong sell” rating in a research report on Wednesday, October 2nd. Two research analysts have rated the stock with a sell rating, one has issued a hold rating and five have assigned a buy rating to the company. The company currently has an average rating of “Hold” and a consensus price target of $12.70.
The company has a market cap of $268.39 million, a PE ratio of -7.95 and a beta of 2.99. The company has a quick ratio of 2.66, a current ratio of 2.66 and a debt-to-equity ratio of 0.26. The business has a 50-day simple moving average of $7.80 and a 200-day simple moving average of $7.05.
About Molecular Templates (NASDAQ:MTEM)
Molecular Templates, Inc, a clinical stage oncology company, focuses on the discovery and development of biologic therapeutics for the treatment of cancer and other diseases. The company primarily develops a pipeline of engineered toxin bodies. Its lead drug candidate is MT-3724 that is in a Phase II clinical trial for the treatment of relapsed/refractory diffuse large B-cell lymphoma; and Phase II clinical trial for treating non-Hodgkin's lymphoma.
Featured Story: Dividend Aristocrat Index
Receive News & Ratings for Molecular Templates Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Molecular Templates and related companies with MarketBeat.com's FREE daily email newsletter.